SCHOTT Pharma AG & Co. KGaA, DE000A3ENQ51

SCHOTT Pharma AG & Co. KGaA: Release according to Article 40, Section 1 of the WpHG [the German Securities Trading Act] with the objective of Europe-wide distribution

Veröffentlicht: 04.11.2025 um 13:18 Uhr, dgap.de

SCHOTT Pharma AG & Co. KGaA / DE000A3ENQ51

EQS Voting Rights Announcement: SCHOTT Pharma AG & Co. KGaA
SCHOTT Pharma AG & Co. KGaA: Release according to Article 40, Section 1 of the WpHG [the German Securities Trading Act] with the objective of Europe-wide distribution

04.11.2025 / 13:18 CET/CEST
Dissemination of a Voting Rights Announcement transmitted by EQS News - a service of EQS Group.
The issuer is solely responsible for the content of this announcement.


Notification of Major Holdings

1. Details of issuer
Name: SCHOTT Pharma AG & Co. KGaA
Street: Hattenbergstraße 10
Postal code: 55122
City: Mainz
Germany
Legal Entity Identifier (LEI): 529900TU48UE99NHEY88

2. Reason for notification
X Acquisition/disposal of shares with voting rights
X Acquisition/disposal of instruments
  Change of breakdown of voting rights
  Other reason:

3. Details of person subject to the notification obligation
Legal entity: T. Rowe Price Group, Inc.
City of registered office, country: Baltimore, Maryland, United States of America (USA)

4. Names of shareholder(s)
holding directly 3% or more voting rights, if different from 3.
 

5. Date on which threshold was crossed or reached:
29 Oct 2025

6. Total positions
  % of voting rights attached to shares
(total of 7.a.)
% of voting rights through instruments
(total of 7.b.1 + 7.b.2)
Total of both in %
(7.a. + 7.b.)
Total number of voting rights pursuant to Sec. 41 WpHG
New 5.01 % 0.00 % 5.01 % 150614616
Previous notification 3.01 % 0.03 % 3.03 % /

7. Details on total positions
a. Voting rights attached to shares (Sec. 33, 34 WpHG)
ISIN Absolute In %
  Direct
(Sec. 33 WpHG)
Indirect
(Sec. 34 WpHG)
Direct
(Sec. 33 WpHG)
Indirect
(Sec. 34 WpHG)
DE000A3ENQ51 0 7549967 0.00 % 5.01 %
Total 7549967 5.01 %

b.1. Instruments according to Sec. 38 (1) no. 1 WpHG
Type of instrument Expiration or maturity date Exercise or conversion period Voting rights absolute Voting rights in %
0 0.00 %
    Total 0 0.00 %

b.2. Instruments according to Sec. 38 (1) no. 2 WpHG
Type of instrument Expiration or maturity date Exercise or conversion period Cash or physical settlement Voting rights absolute Voting rights in %
0 0.00 %
      Total 0 0.00 %

8. Information in relation to the person subject to the notification obligation
  Person subject to the notification obligation is not controlled nor does it control any other undertaking(s) that directly or indirectly hold(s) an interest in the (underlying) issuer (1.).
X Full chain of controlled undertakings starting with the ultimate controlling natural person or legal entity:

Name % of voting rights (if at least 3% or more) % of voting rights through instruments (if at least 5% or more) Total of both (if at least 5% or more)
T. Rowe Price Group, Inc. % % %
T. Rowe Price Associates, Inc. % % %
T. Rowe Price International Ltd 5.01 % % 5.01 %

9. In case of proxy voting according to Sec. 34 para. 3 WpHG
(only in case of attribution of voting rights in accordance with Sec. 34 para. 1 sent. 1 No. 6 WpHG)

Date of general meeting:
Holding total positions after general meeting (6.) after annual general meeting:
Proportion of voting rights Proportion of instruments Total of both
% % %

10. Other explanatory remarks:
 

Date
03 Nov 2025



04.11.2025 CET/CEST The EQS Distribution Services include Regulatory Announcements, Financial/Corporate News and Press Releases.
View original content: EQS News
Language: English
Company: SCHOTT Pharma AG & Co. KGaA
Hattenbergstraße 10
55122 Mainz
Germany

 
End of News EQS News Service

2223614  04.11.2025 CET/CEST
en | DE000A3ENQ51 | SCHOTT PHARMA AG & CO. KGAA | boerse | 68322080 |

Weitere Meldungen

Schott Pharma erhöht Prognose nach starkem Quartal - Aktie springt an (Kurs aktualisiert)MAINZ - Der Pharmazulieferer Schott Pharma DE000A3ENQ51 hat nach einem starken Quartal die Prognosen für das Gesamtjahr erhöht. (Boerse, 09.07.2026 - 16:52) weiterlesen...

ANALYSE-FLASH: Jefferies belässt Schott Pharma auf 'Hold' - Ziel 17,30 Euro Das Analysehaus Jefferies hat die Einstufung für Schott Pharma DE000A3ENQ51 nach vorläufigen Zahlen zum dritten Geschäftsquartal auf "Hold" mit einem Kursziel von 17,30 Euro belassen. (Boerse, 09.07.2026 - 09:50) weiterlesen...

Schott Pharma erhöht Prognose nach starkem Quartal - Aktie springt an Der Pharmazulieferer Schott Pharma DE000A3ENQ51 hat nach einem starken Quartal die Prognosen für das Gesamtjahr erhöht. (Boerse, 09.07.2026 - 09:26) weiterlesen...

ANALYSE-FLASH: RBC hebt Schott Pharma auf 'Outperform' - Ziel hoch auf 21 Euro Die kanadische Bank RBC hat das Kursziel für Schott Pharma DE000A3ENQ51 von 18 auf 21 Euro angehoben und die Aktien von "Sector Perform" auf "Outperform" hochgestuft. (Boerse, 09.07.2026 - 08:35) weiterlesen...

AKTIE IM FOKUS: Schott Pharma springen an - Analystenlob nach Prognoseerhöhung Die Aktien von Schott Pharma DE000A3ENQ51 haben am Donnerstagmorgen im vorbörslichen Handel ein Jahreshoch erklommen. (Boerse, 09.07.2026 - 08:19) weiterlesen...

Schott Pharma erhöht Prognosen für Gesamtjahr nach starkem Quartal Der Pharmazulieferer Schott Pharma DE000A3ENQ51 hat nach einem starken Quartal die Prognosen für das Gesamtjahr erhöht. (Boerse, 08.07.2026 - 19:08) weiterlesen...